With A Breakout On The Line, Gilead Sciences Reports Massive Cancer Drug SalesInvestors Business Daily • 10/27/22
Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy® for the Treatment of People Living With HIV With a Range of ComorbiditiesBusiness Wire • 10/24/22
Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood CancersBusiness Wire • 10/20/22
Gilead Presents Real-World and Long-Term Data From HIV Research Programs at HIV Glasgow 2022Business Wire • 10/18/22
Kite's Yescarta First CAR T-cell Therapy to Receive European Marketing Authorization for Use in Second-Line Diffuse Large B-cell Lymphoma and High-grade B-cell LymphomaBusiness Wire • 10/17/22
Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific AntibodiesBusiness Wire • 10/17/22
Gilead Sciences to Release Third Quarter 2022 Financial Results on Thursday, October 27, 2022Business Wire • 10/13/22